Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.

导出 LinkOut

翻译打印收藏纠错

作者： Olga,De Santis ^[1] ; Régine,Audran ^[2] ; Emilie,Pothin ^[3] ; Loane,Warpelin-Decrausaz ^[4] ; Laure,Vallotton ^[4] ; Grégoire,Wuerzner ^[4] ; Camille,Cochet ^[5] ; Daniel,Estoppey ^[5] ; Viviane,Steiner-Monard ^[2] ; Sophie,Lonchampt ^[5] ; Anne-Christine,Thierry ^[2] ; Carole,Mayor ^[2] ; Robert T,Bailer ^[6] ; Olivier Tshiani,Mbaya ^[6] ; Yan,Zhou ^[6] ; Aurélie,Ploquin ^[6] ; Nancy J,Sullivan ^[6] ; Barney S,Graham ^[6] ; François,Roman ^[7] ; Iris,De Ryck ^[7] ; W Ripley,Ballou ^[7] ; Marie Paule,Kieny ^[8] ; Vasee,Moorthy ^[8] ; François,Spertini ^[2] ; Blaise,Genton ^[9]

作者单位： Policlinique Médicale Universitaire, Lausanne, Switzerland. Electronic address: olga.de-santis@hospvd.ch. ^[1] Division of Immunology and Allergy, Lausanne University Hospital, Switzerland. ^[2] Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland. ^[3] Clinical Trial Unit, Lausanne University Hospital, Switzerland. ^[4] Policlinique Médicale Universitaire, Lausanne, Switzerland. ^[5] Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. ^[6] GSK Vaccines, Rixensart, Belgium. ^[7] WHO, Geneva, Switzerland. ^[8] Policlinique Médicale Universitaire, Lausanne, Switzerland; Infectious Diseases Service, Department of Medicine, Lausanne University Hospital, Switzerland; Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland. ^[9]